Novartis Ag

Novartis Pharma Ag

Christoph Heusser

Stefanie Urlinger

Julia Neugebauer

James Rush

Eveline Schaadt

Karen Vincent

Maximilian Woisetschlaeger

Christoph Schwaerzler

Marta Cosenza

Gabriela Wochnik-Veltrup

Jose M Carballido Herrera

Ingo Klagge

Stefan Hartle

Andrea Polzer

Michael Otto Bardroff

Ute Jaeger

José M Carballido Herrera

Daniela Della Ducata

Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Anti-BAFFR antibody formulations and methods of use thereof

The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies

Nucleic acids encoding silent Fc variants of anti-CD40 antibodies

Silent Fc variants of anti-CD40 antibodies

Anti-BAFFR antibody formulations

The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

Compositions and methods of use for therapeutic antibodies

Anti-CD40 antibodies have not been reported to induce hemostatic events in patients, however elevations in pancreatic enzymes in B cell lymphoma patients receiving the anti-CD40 Ab Chir12.12 and the possible risk of pancreatitis precludes the use of this Fc-competent anti-CD40 antibody in chronic autoimmune disease and transplantation for safety reasons. We therefore generated Fc-silent IgG1 anti-CD40 antibodies (mAb1, mAb2 and mAb3) unable to mediate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) both in vitro and in vivo. mAb1 was able to prolong non-human primate renal allograft survival in combination with sub-therapeutic doses of cyclosporine. In addition, mAb1 was able to completely suppress primary and secondary antibody responses to immunization with a T cell-dependent antigen. Crucially, there was no evidence of hemostatic events or abnormal pancreatic histology in either the transplant or immunization study. Collectively these results suggest mAb1 would be a safe and efficacious therapeutic, and could be used to treat patients suffering from B lymphocyte and antigen presenting cell driven autoimmune disease or undergoing allograft transplant where CD4O-CD154 interactions are involved in contributing to pathology.

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN&#x3b3; production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Anti-IL12R&#x3b2;1 antibodies and their use in treating autoimmune and inflammatory disorders

Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12R&#x3b2;2 chain) as well as IL23 receptor (together with IL23R&#x3b1; chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN&#x3b3; production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Therapeutic antibodies binding IL12R&#x3b2;1

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN&#x3b3; production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Growing community of inventors

Oberwil, Switzerland

Christoph Heusser